Navigation Links
West Nile virus' spread through nerve cells linked to serious complication
Date:10/18/2007

Oct. 18, 2007 -- Scientists believe they have found an explanation for a puzzling and serious complication of West Nile virus infection.

Researchers at Washington University School of Medicine in St. Louis and Utah State University showed that West Nile virus can enter a nerve cell, replicate and move on to infect other nearby nerve cells. Viruses traveling this infectious pathway can break into the central nervous system, triggering a condition known as acute flaccid paralysis that leaves one or more limbs limp and unresponsive. No treatment is currently available for this complication. Patients must undergo rehabilitation to relearn to use the affected limb.

Injection of a West Nile virus antibody, created by Washington University and a private biotechnology firm, blocked the complication in laboratory animals. The results appear online in the Proceedings of the National Academy of Sciences.

Preliminary data suggests there will be approximately 4,000 to 5,000 severe West Nile virus infections in the United States in 2007. First isolated in Africa in 1937, West Nile spread to the Middle East, Europe, and Asia before arriving in the United States in 1999. Most infections with the virus are mild or symptom-free, but infections in people with weakened immune systems and those over 50 sometimes lead to serious complications or death.

Senior author Michael Diamond, M.D., Ph.D., associate professor of molecular microbiology, of pathology and immunology and of medicine, began the new study because of a puzzling contrast in the ways West Nile virus infection affects the central nervous system.

One form of infection, encephalitis, causes inflammation of the brain and leads to fever, headaches, weakness and seizures. It is much more likely to occur in patients who are elderly or have weakened or suppressed immune systems. The other form of infection, acute flaccid paralysis, strikes patients with weakened immune systems but also affects a signif
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University in St. Louis
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Association of herpesvirus with lung disorder questioned
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Elusive HIV shape change revealed; Key clue to how virus infects cells
4. Scientists Replicate Hepatitis C Virus in Laboratory
5. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
6. Live Recombinant Adenovirus Vaccine Technique Explored
7. Marburg virus disease in Angola - update
8. Study: Soap And Water Work Best In Ridding Hands Of Disease Viruses
9. Studies reveal methods viruses use to sidestep immune system
10. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
11. Norovirus, AIDS vaccine and Hepatitis Virus

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...heart pumps some 250 million liters of blood throu...ibers of the heart have to be extremely durable. T..., vice chair of the Department of Medicine III at .... H. A. Katus), has discovered a protein that is r...lar unit, the sarcomere. In cooperation with other...
(Date:11/24/2009)...prescribed by traditional healers in Brazil to tre...pain to fever and flu. , Now for the first time, ... to scientifically prove the pain relieving proper...lian mint. , Testing this ancient South American ...Rocha was able to show that when prepared as a ,te...
(Date:11/24/2009)...ein that may help gut bacteria bind to the gastroi...iotic producers to identify strains that are likel...need to interact with cells lining the gut to have...es in the gut they are more likely to stick around...halie Juge from the Institute of Food Research. I...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 1Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 2Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 3Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 4Data Published in The New England Journal of Medicine Support Use of Raxibacumab 28ABthrax 28TM 29 29 for the Treatment of Inhalation Anthrax 12949 5Go Healthy Announces Negotiations With Bottling Facilities 51183 1Go Healthy Announces Negotiations With Bottling Facilities 51183 2Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 12948 1Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast 12948 2
...ditions to come , Human-induced climate change i...titudes. To assess whether the onset of drier con...wly developed multicentury tree ring records from ...on drought in northwestern Africa. Using a new set...ntica) and Aleppo pines ( Pinus halepensis ), the ...
...ellow. Do you gun the engine and speed through the...their green, or do you slow down and wait your tur...lity, according to new research from Tel Aviv Univ...he Department of Zoology at Tel Aviv University, r...le adopt risk-taking behaviors similar to those of...
...stigating exactly how chemotherapy drugs kill canc...test the effectiveness of safer new agents. , Dr S...y of Manchester,s Faculty of Life Sciences have ta...otic drugs, which are used extensively for breast ...s, which includes the agent taxol, has been used c...
Other Biology News:AGU journal highlights -- August 6, 2008 2AGU journal highlights -- August 6, 2008 3AGU journal highlights -- August 6, 2008 4AGU journal highlights -- August 6, 2008 5AGU journal highlights -- August 6, 2008 6AGU journal highlights -- August 6, 2008 7Humans' response to risk can be unnecessarily dangerous, finds Tel Aviv University study 2How chemo kills tumors: research to reduce side effects 2How chemo kills tumors: research to reduce side effects 3
(Date:11/24/2009)..., CALGARY and BLENHEIM, Ontario, Nov. 24 /PRNews...ed today it is acquiring the assets of Hyland Seed...tario. The addition of Hyland Seeds will further e...the company anticipates the introduction of Smart...de Tolerant Trait Technology in corn in 2012. The ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November ... (Nasdaq: DCGN ) today announced the approval of a...cy Court for the District of Delaware,(the "Bankru...etition for,relief under Chapter 11 of the United ..., The orders issued by the Bankruptcy Cou...
(Date:11/24/2009)...SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.a...opmentAuthority(OPDA)wererecentlyawarded$2millionb...oard(CERB)inaprivate/publicpartnershiptoconstructt...colnCounty,WA. ,, "Thisinvestmentwillsignifican...70greenjobstoLincolnCounty,"saidBlueMarbleEnergyCE...
(Date:11/24/2009)..., DUBLIN, November 24 /PRNewswire-FirstCall...obal specialty biopharmaceutical company, today,an...n Medicines Agency for,velaglucerase alfa, the com...or the treatment of Type 1 Gaucher disease. This i...e alfa that has been submitted, with previous,subm...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...edic Imaging, PARIS and ATLANTA, Oct. 9 Biospace...arance from the Food and Drug Administration,(FDA)...nited States for 2D,imaging use. EOS 2D|3D techno...ging,allowing images to be obtained with a low dos...al imaging, permitting full-body, uninterrupted di...
...echnology company translating the complexity of hu..., today announced that Andrea Matthews,(age 25), m... Mass High,Tech for its "People to Watch Under 30....idual like Andrea as,part of our team," said Dr. K..."She has been a go-getter ever since she started a...
...ey, OAK BROOK, Ill. and CARY, N.C., Oct. 9 The U...ce of academic medical centers and,their affiliate...ent,technology and services for academic and resea...rship to provide organizations participating in,UH...a robust, easy-to-use,procurement engine to stream...
Other Biology Technology:FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 2FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 3FDA Clears Biospace med's Revolutionary Low Dose Xray Imager 4Genstruct's Andrea Matthews Selected for Mass High Tech's 'People to Watch Under 30' 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 2University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement 3
10% BSA in TBS from Upstate
Rabbit Anti-Aortic Elastin Polyclonal Antibody, Unconjugated from Abcam
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Rabbit Anti-MEF2A, phospho (Thr312) Antibody, Unconjugated from Spring Bioscience
Biology Products: